Currently Viewing:
Currently Reading
Researchers Identify New, Overlooked Target to Treat Multiple Sclerosis
December 27, 2018 – Laura Joszt
Food Allergies Associated With More Relapses in Patients With MS
December 21, 2018 – Laura Joszt
FDA Warns of Rare Risks of MS Drug Alemtuzumab
December 20, 2018 – Jaime Rosenberg
CDC Launching Surveillance System to Study Multiple Sclerosis, Other Neurological Conditions
December 13, 2018 – Jaime Rosenberg
Ibrutinib Regimens Have Superior PFS Compared With Chemoimmunotherapy in Older Patients With Untreated CLL
December 13, 2018 – David Bai, PharmD
Some Lifestyle Factors Positively Impact Depression in People With Multiple Sclerosis
December 09, 2018 – Laura Joszt
Researchers Demonstrate Efficacy of EEG-Based Test for Measuring Pain
December 07, 2018 – Alison Rodriguez
International Consensus on Timely Care for Multiple Sclerosis
December 07, 2018 – David Bai, PharmD
Patients Who Stop Taking Gilenya May Experience Worsening of Multiple Sclerosis
December 03, 2018 – Laura Joszt

Researchers Identify New, Overlooked Target to Treat Multiple Sclerosis

Laura Joszt
Mature oligodendrocytes have been overlooked in the past as a way to treat multiple sclerosis, but a new study has found they might be able to help with remyelinating axons the same as new oligodendrocytes.
New oligodendrocytes from progenitor cells may not be the only way to repair myelin, which is critical for treating multiple sclerosis (MS). Researchers have discovered that mature oligodendrocytes that are partially injured may be able to help repair myelin. The study was published in the Proceedings of the National Academy of Sciences.

Demylineation results in symptoms associated with MS, such as numbness, weakness, and vision problems. Oligodendrocytes are cells that can reach out to nearby axons and wrap them in a protective myelin sheath.

Previous consensus had been that the only way to bring myelin back to an axon is with new oligodendrocytes, and MS treatments focused on remyelineation have focused on using progenitor cells to spur myelin development.

The researchers used large animal models, including a nonhuman primate, to show that partially injured oligodendrocytes can repair myelin. However, the adult oligodendrocytes need to still have internodes, which are connections to surviving myelin segments on other axons.

“If this cell is still biologically active and maintaining these internodes, it can re-extend processes out to these demyelinated segments,” lead author Ian Duncan, PhD, BVMS, a neuroscientist at the University of Wisconsin–Madison’s School of Veterinary Medicine, said in a statement. “Those processes can make new myelin sheaths, which end up being thinner and shorter than the previous internodes.”

While the discovery that mature oligodendrocytes still have the ability to repair may open new opportunities to slow or reverse MS, Duncan noted that the process may not play out fast enough in humans or too many oligodendrocytes may be losing their internodal connections so that they become inactive or die.

Still, having a new target means new therapeutic approaches, such as drugs that rally oligodendrocytes to create new lifelines.

“In fighting complex diseases, such as MS, the more tools you have on hand, the better,” Duncan said. “If these adult cells are recruitable in some fashion, we should be looking at ways to do it.”


Duncan ID, Radcliff AB, Heidari M, Kidd G, August BK, Wierenga LA. The adult oligodendrocyte can participate in remyelination. Proc Natl Acad Sci USA. 2018;115(50):e11807-e11816. doi: 10.1073/pnas.1808064115.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up